Future Farm (CSE:FFT) has announced the creation of a cannabis advisory board, selecting John Sweeney as its chief operating officer.
As quoted in the press release:

The Company is also pleased to announce that it has selected Mr. Chris Lesh as the Cannabis Advisory Board’s first member. Mr. Lesh has over 10 years experience within the cannabis cultivation and dispensary industry in Washington State. Mr. Lesh previously served as Production Director for Privateer Holdings, Inc. (“Privateer”) and played an important role in its success. While working for Privateer, Mr. Lesh worked with Mr. Sweeney and was responsible for the operational oversight of cannabis production at Tilray’s Vancouver facility.Tilray, which is owned by Privateer, is a global leader in medical cannabis research and production dedicated to advancing the science and safety of cannabinoid medicine for patients with a diverse range of conditions including epilepsy, cancer, chronic pain and multiple sclerosis. Tilray operates one of the largest and most sophisticated medicinal cannabis research and production facilities in the world and offers pharmaceutical grade medical cannabis products to patients, pharmacies and researchers in Australia, Canada, the European Union and the Americas.
In addition to overseeing cannabis production at Tilray, Mr. Lesh was also responsible for the sourcing of additional production capacity throughout the west coast and Canada. His knowledge, background, and expertise make Mr. Lesh a strategic addition to Future Farm’s Cannabis Advisory Board, as he will be able to add value on several different initiatives. Mr. Lesh adds great experience when it comes to sourcing capital, increasing production capacity, and setting up the facilities to operate efficiently and effectively.
“We are pleased to welcome Chris Lesh to our newly created Cannabis Advisory Board and look forward to working with him,” says Mr. William Gildea, Future Farm Technologies Inc.’s CEO and Chairman. “As we prepare to build out or cultivation business, having Chris on our Board will allow us to gain a deeper understanding of the Cannabis business the state of the market and industry trends.”

Click here to read the full press release.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less